帕金森病发病机制及诊断与治疗转化研究进展  

Progress of translational research on the pathogenesis, diagnosis and treatment of Parkinson's disease

作　　者：王刚[1] 崔海伦 刘军[1] 丁健青[1] 肖勤[1] 马建芳[1] 陈生弟[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院神经科上海交通大学医学院神经病学研究所,200025

出　　处：《中国现代神经疾病杂志》2018年第1期19-24,共6页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：国家重点基础研究发展计划(973计划)项目(项目编号:2011CB504100);国家自然科学基金重点资助项目(项目编号:81430022);国家自然科学基金重大研究计划项目(项目编号:91332107);国家自然科学基金资助项目(项目编号:81371407);国家自然科学基金资助项目(项目编号:81129018)~~

摘　　要：帕金森病是中老年人群常见的神经变性病,其高患病率、高病残率和慢性病程的特点使帕金森病早期诊断、治疗和预防研究成为神经科学领域共同关注的焦点和热点。我国国民经济和社会发展第十二个五年规划(简称"十二五")时期,上海交通大学医学院附属瑞金医院陈生弟教授研究团体利用前期已建立的帕金森病临床资源和应用基础研究平台,着眼帕金森病基础与临床研究进展,围绕发病机制和治疗,立足转化医学,获得许多创新性发现:(1)VPS35基因参与线粒体分裂的新细胞机制,提示线粒体分裂失衡可能与家族性或散发性帕金森病发病密切相关。(2)自主神经功能障碍等帕金森病非运动症状和多巴胺转运体PET显像可以作为评价特发性快速眼动睡眠期行为障碍临床预后的生物学标志物,并进行帕金森病病死率和死因调查,对帕金森病预后和转归具有重要参考意义。(3)主持制定我国首部《中国帕金森病治疗指南(第一~三版)》和《中国帕金森病的诊断标准(2016版)》,为进一步合理、规范我国帕金森病诊断与治疗发挥重要指导和推动作用。Parkinson＇s disease（PD） is one of the most common neurodegenerative diseases.Because of its high prevalence, severe disability and chronic course of disease, it has become one of the most important research focuses in modern medicine ranging from early diagnosis and treatment to prevention. During the period of Twelfth Five.Year Plan for National Economic and Social Development,our team made use of previously established PD Clinical Databse and applying basic research platform,focused on clinical and basic development of PD, and further extended our investigation into the field of pathogenesis, diagnosis and treatment in PD with characteristics of translational medicine. Several progresses have been made in a multiple of aspects： 1） a novel cellular mechanism of mitochondrial fission with the involvement of VPS35 gene, dysregulation of which might be involved in the pathogenesis of familial and sporadic PD. 2） The predictive value of autonomic dysfunction and dopamine transporter（DAT） PET in identifying patients with idiopathic rapid eye movement sleep behavior disorder（iRBD） with a high risk of progressing into neurodegenerative synucleinopathy diseases could form a basis for future disease.prevention trials. Additionally, we initiated the research on PD mortality rate and analyzed the common reasons of death, which added to the evidence of clinical prognosis and progression. 3） We issued the first, second and third versions of ＂Chinese guidelines for treatment of Parkinson＇s disease＂, as well as the ＂Diagnostic criteria of Parkinson＇s disease in China（2016 edition）＂, which could help improve the diagnostic ability and optimize the clinical treatment of PD in China.

关 键 词：帕金森病 中国 综述 

分 类 号：R742.5[医药卫生—神经病学与精神病学]